Denali Therapeutics Inc. Non Peo Neo Avg Total Comp Amt
Denali Therapeutics Inc. (DNLI) reported Non Peo Neo Avg Total Comp Amt of $4.04 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-21.
Financial Statements › Notes
ecd:NonPeoNeoAvgTotalCompAmt · last filed 2026-04-21
| Period end | Non Peo Neo Avg Total Comp Amt 12 month |
|---|---|
| 2025-12-31 | $4.04M DEF 14A · filed 2026-04-21 |
| 2024-12-31 | $4.02M DEF 14A · filed 2026-04-21 |
| 2023-12-31 | $4.17M DEF 14A · filed 2026-04-21 |
| 2022-12-31 | $5.22M DEF 14A · filed 2026-04-21 |
| 2021-12-31 | $6.55M DEF 14A · filed 2026-04-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |